Lv2
160 积分 2022-06-22 加入
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
17小时前
已完结
Cell death, IL-1 cytokines, and tumor progression
9天前
已完结
Discovery and Characterization of RP03707: A Highly Potent and Selective KRASG12D PROTAC
1个月前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer
4个月前
已完结
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
4个月前
已完结
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
5个月前
已完结
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
6个月前
已完结
CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer
6个月前
已完结
Cancer cell metabolism and antitumour immunity
6个月前
已完结
皖公网安备34019202002308
